A Phase 1B, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have progressed followinIn

Clinical Trial Grant

Duke Scholars

Principal Investigator Andrew John Armstrong Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Genentech, Inc.

Start Date

March 2, 2017

End Date

September 7, 2021

Administered By

Duke Cancer Institute

Awarded By

Genentech, Inc.

Start Date

March 2, 2017

End Date

September 7, 2021